15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 14 firms covering Protagonist Therapeutics Inc, 14 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $82.00 to $190.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $144.29 sits 1% below the current $145.87. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 13 to 14 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.43 next quarter toward $-0.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 ratings
Strong Buy
Strong Buy00%
Buy14100%
Hold00%
Sell00%
Strong Sell00%
Based on 14 analysts giving stock ratings to Protagonist Therapeutics Inc.
As of Sep, 14 of 14 firms rate PTGX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PTGX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.43
Range $-0.90 – $0.55 · 10 analysts · -37% YoY
Next period, 10 analysts expect Protagonist Therapeutics Inc to earn $-0.43 a share (range $-0.90 – $0.55), versus $-0.69 a year earlier. Full-year consensus is $4.79, growing to $-0.20 the year after.
REVENUE · NEXT QUARTER
$36.3M
Range $2.7M – $162.1M · 10 analysts · +388% YoY
Revenue is expected to reach $36.3M (range $2.7M – $162.1M), +387.7% year-over-year. Full-year consensus is $542.3M, rising to $203.4M next year.
Top analysts covering Protagonist Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PTGX.
#1
Jonathan Wolleben
JMP Securities · Rank #29
Buy
$165.00+13.1% to target
Overall win rate
47%
+ Follow
#2
Roger Song
Jefferies · Rank #101
Buy
$118.00-19.1% to target
Overall win rate
43%
+ Follow
#3
Douglas Tsao
HC Wainwright & Co. · Rank #248
Buy
$170.00+16.5% to target
Overall win rate
35%
+ Follow
#4
Etzer Darout
Barclays
Buy
$180.00+23.4% to target
Coverage
—
+ Follow
#5
SD
Srikripa Devarakonda
Truist Securities
Buy
$170.00+16.5% to target
Coverage
—
+ Follow
PTGX stock forecast FAQ
What is PTGX's average 12-month price target?+
The 14 analysts with a live target average $144.29 for Protagonist Therapeutics Inc over the next 12 months, ranging from a $190.00 high to a $82.00 low.
Is PTGX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 14 analyst ratings, 14 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PTGX?+
The Street-high target is $190.00 (BMO Capital), and the Street-low is $82.00 (BTIG). The average of all 14 active targets is $144.29.
How many Wall Street analysts cover PTGX?+
14 analysts have an active rating on Protagonist Therapeutics Inc, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering PTGX?+
Among analysts who currently cover PTGX, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #29). Their current call is Buy with a $165.00 target.
What is Protagonist Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.43 per share (range $-0.90 – $0.55) across 10 analysts. Full-year EPS is projected at $4.79, rising to $-0.20 the following year.
How much revenue is Protagonist Therapeutics Inc expected to report next quarter?+
Consensus revenue is $36.3M (range $2.7M – $162.1M). Full-year revenue is projected at $542.3M, growing to $203.4M next year.
Have analysts been upgrading or downgrading PTGX lately?+
As of Sep, 14 of 14 firms rate PTGX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PTGX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
